TNFRSF1B and ovarian cancer: Overabundance of TNFR2+ Tregs creates a potent immunosuppressive microenvironment associated with negative patient outcomes in diverse cancers, such as acute myeloid leukemia, lung cancer, ovarian cancer, and colorectal cancer (16–20).